A novel class of antibodies known as nanobodies has been discovered, offering hope for treating cystic fibrosis. These nanobodies are smaller than traditional antibodies. The project examining this new approach is led by the Université Libre de Bruxelles (ULB) with support from the Air Liquide Foundation.
Cystic fibrosis is caused by a defect in the cell membrane transporter, which is unable to correctly transport chloride ions in the lungs. This is due to a genetic mutation that prevents the transporter from reaching the surface of the lung cell.
Cystic fibrosis is caused by a defect in the cell membrane transporter
The goal of the research: to identify nanobodies capable of restoring the body's ability to transport chloride ions, which is missing in patients suffering from this condition.
A benefit for patients: this therapeutic approach would eliminate most symptoms of the disease, including respiratory symptoms.
Founded in 1834, the Université Libre de Bruxelles (ULB) is a multi-cultural university. More than one third of its students and researchers are international. Since it was founded, the ULB's research programs have received several awards for excellence, including four Nobel Prizes, one Fields Medal (for excellence in mathematics) and two Marie Curie Awards.